No improvement in long-term survival over time for chronic lymphocytic leukemia patients in stereotyped subsets 1 and 2 treated with chemo(immuno)therapy
| Authors | |
|---|---|
| Year of publication | 2018 |
| Type | Article in Periodical |
| Magazine / Source | haematologica |
| MU Faculty or unit | |
| Citation | |
| Web | http://www.haematologica.org/content/haematol/early/2017/12/18/haematol.2017.182634.full.pdf |
| Doi | http://dx.doi.org/10.3324/haematol.2017.182634 |
| Keywords | CYCLOPHOSPHAMIDE; FLUDARABINE; RITUXIMAB; CHEMOIMMUNOTHERAPY; TRIAL |
| Description | The overall survival (OS) of patients with chronic lymphocytic leukemia (CLL) has improved over the last decades mainly due to advances in the understanding of the disease biology and the introduction of novel therapeutic approaches(1). In the present retrospective study we investigated trends in OS in subgroups of cases defined by genetic and immunogenetic features aiming at addressing the question whether advances in chemoimmunotherapy had a uniform impact across all CLL patients. We found that such advances have translated into prolonged OS in all prognostic subgroups examined except those carrying TP53 abnormalities, as expected, but also those assigned to stereotyped subsets #1 and #2, that are generally devoid of such gene aberrations. This latter finding, reported here for the first time, indicates the need for alternative treatment options for these patients. |
| Related projects: |